Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface

S Malhotra, D Hayes Jr, DJ Wozniak - Clinical microbiology …, 2019 - Am Soc Microbiol
In human pathophysiology, the clash between microbial infection and host immunity
contributes to multiple diseases. Cystic fibrosis (CF) is a classical example of this …

Immune Responses to Pseudomonas aeruginosa Biofilm Infections

C Moser, PØ Jensen, K Thomsen, M Kolpen… - Frontiers in …, 2021 - frontiersin.org
Pseudomonas aeruginosa is a key pathogen of chronic infections in the lungs of cystic
fibrosis patients and in patients suffering from chronic wounds of diverse etiology. In these …

Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model

M Cafora, G Deflorian, F Forti, L Ferrari, G Binelli… - Scientific reports, 2019 - nature.com
Cystic fibrosis (CF) is a hereditary disease due to mutations in the CFTR gene and causes
mortality in humans mainly due to respiratory infections caused by Pseudomonas …

Biofilms and host response–helpful or harmful

C Moser, HT Pedersen, CJ Lerche, M Kolpen, L Line… - Apmis, 2017 - Wiley Online Library
Biofilm infections are one of the modern medical world's greatest challenges. Probably, all
non‐obligate intracellular bacteria and fungi can establish biofilms. In addition, there are …

[HTML][HTML] Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis

HH Öz, EC Cheng, C Di Pietro, T Tebaldi, G Biancon… - Cell reports, 2022 - cell.com
Persistent neutrophil-dominated lung inflammation contributes to lung damage in cystic
fibrosis (CF). However, the mechanisms that drive persistent lung neutrophilia and tissue …

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function

S Zhang, CL Shrestha, BT Kopp - Scientific reports, 2018 - nature.com
Despite the addition of cystic fibrosis transmembrane conductance regulator (CFTR)
modulators to the cystic fibrosis (CF) treatment regimen, patients with CF continue to suffer …

Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis

C Gabillard-Lefort, M Casey, AMA Glasgow… - American journal of …, 2022 - atsjournals.org
Rationale: Cystic fibrosis (CF) is caused by mutations in the CFTR (CF transmembrane
conductance regulator) gene and is characterized by sustained inflammation. ATP triggers …

Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages

DS Aridgides, DL Mellinger, LL Gwilt, TH Hampton… - Scientific Reports, 2023 - nature.com
Macrophage dysfunction has been well-described in Cystic Fibrosis (CF) and may contribute
to bacterial persistence in the lung. Whether CF macrophage dysfunction is related directly …

[PDF][PDF] The impact of highly effective modulator therapy on cystic fibrosis microbiology and inflammation

LJ Caverly, SA Riquelme, KB Hisert - Clinics in chest medicine, 2022 - Elsevier
Highly-effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator
therapy (HEMT) corrects the underlying molecular defect causing cystic fibrosis (CF) …

Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations

S Lara-Reyna, J Holbrook, HH Jarosz-Griffiths… - Cellular and Molecular …, 2020 - Springer
Cystic fibrosis (CF) is one of the most common life-limiting recessive genetic disorders in
Caucasians, caused by mutations in the cystic fibrosis transmembrane conductance …